Cargando…
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on INSTI-associated drug resistance mutations (D...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536831/ https://www.ncbi.nlm.nih.gov/pubmed/37766338 http://dx.doi.org/10.3390/v15091932 |
_version_ | 1785112961213267968 |
---|---|
author | Tao, Kaiming Rhee, Soo-Yon Chu, Carolyn Avalos, Ava Ahluwalia, Amrit K. Gupta, Ravindra K. Jordan, Michael R. Shafer, Robert W. |
author_facet | Tao, Kaiming Rhee, Soo-Yon Chu, Carolyn Avalos, Ava Ahluwalia, Amrit K. Gupta, Ravindra K. Jordan, Michael R. Shafer, Robert W. |
author_sort | Tao, Kaiming |
collection | PubMed |
description | Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on INSTI-associated drug resistance mutations (DRMs) selected by DTG-containing ART regimens. Methods: We reviewed studies published through July 2023 to identify those reporting emergent major INSTI-associated DRMs in INSTI-naïve PLWH receiving DTG and those containing in vitro DTG susceptibility results using a standardized assay. Results: We identified 36 publications reporting 99 PLWH in whom major nonpolymorphic INSTI-associated DRMs developed on a DTG-containing regimen and 21 publications containing 269 in vitro DTG susceptibility results. DTG-selected DRMs clustered into four largely non-overlapping mutational pathways characterized by mutations at four signature positions: R263K, G118R, N155H, and Q148H/R/K. Eighty-two (82.8%) viruses contained just one signature DRM, including R263K (n = 40), G118R (n = 24), N155H (n = 9), and Q148H/R/K (n = 9). Nine (9.1%) contained ≥1 signature DRM, and eight (8.1%) contained just other DRMs. R263K and G118R were negatively associated with one another and with N155H and Q148H/K/R. R263K alone conferred a median 2.0-fold (IQR: 1.8–2.2) reduction in DTG susceptibility. G118R alone conferred a median 18.8-fold (IQR:14.2–23.4) reduction in DTG susceptibility. N155H alone conferred a median 1.4-fold (IQR: 1.2–1.6) reduction in DTG susceptibility. Q148H/R/K alone conferred a median 0.8-fold (IQR: 0.7–1.1) reduction in DTG susceptibility. Considerably higher levels of reduced susceptibility often occurred when signature DRMs occurred with additional INSTI-associated DRMs. Conclusions: Among INSTI-naïve PLWH with VF and treatment emergent INSTI-associated DRMs, most developed one of four signature DRMs, most commonly R263K or G118R. G118R was associated with a much greater reduction in DTG susceptibility than R263K. |
format | Online Article Text |
id | pubmed-10536831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105368312023-09-29 Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review Tao, Kaiming Rhee, Soo-Yon Chu, Carolyn Avalos, Ava Ahluwalia, Amrit K. Gupta, Ravindra K. Jordan, Michael R. Shafer, Robert W. Viruses Review Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on INSTI-associated drug resistance mutations (DRMs) selected by DTG-containing ART regimens. Methods: We reviewed studies published through July 2023 to identify those reporting emergent major INSTI-associated DRMs in INSTI-naïve PLWH receiving DTG and those containing in vitro DTG susceptibility results using a standardized assay. Results: We identified 36 publications reporting 99 PLWH in whom major nonpolymorphic INSTI-associated DRMs developed on a DTG-containing regimen and 21 publications containing 269 in vitro DTG susceptibility results. DTG-selected DRMs clustered into four largely non-overlapping mutational pathways characterized by mutations at four signature positions: R263K, G118R, N155H, and Q148H/R/K. Eighty-two (82.8%) viruses contained just one signature DRM, including R263K (n = 40), G118R (n = 24), N155H (n = 9), and Q148H/R/K (n = 9). Nine (9.1%) contained ≥1 signature DRM, and eight (8.1%) contained just other DRMs. R263K and G118R were negatively associated with one another and with N155H and Q148H/K/R. R263K alone conferred a median 2.0-fold (IQR: 1.8–2.2) reduction in DTG susceptibility. G118R alone conferred a median 18.8-fold (IQR:14.2–23.4) reduction in DTG susceptibility. N155H alone conferred a median 1.4-fold (IQR: 1.2–1.6) reduction in DTG susceptibility. Q148H/R/K alone conferred a median 0.8-fold (IQR: 0.7–1.1) reduction in DTG susceptibility. Considerably higher levels of reduced susceptibility often occurred when signature DRMs occurred with additional INSTI-associated DRMs. Conclusions: Among INSTI-naïve PLWH with VF and treatment emergent INSTI-associated DRMs, most developed one of four signature DRMs, most commonly R263K or G118R. G118R was associated with a much greater reduction in DTG susceptibility than R263K. MDPI 2023-09-15 /pmc/articles/PMC10536831/ /pubmed/37766338 http://dx.doi.org/10.3390/v15091932 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tao, Kaiming Rhee, Soo-Yon Chu, Carolyn Avalos, Ava Ahluwalia, Amrit K. Gupta, Ravindra K. Jordan, Michael R. Shafer, Robert W. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review |
title | Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review |
title_full | Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review |
title_fullStr | Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review |
title_full_unstemmed | Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review |
title_short | Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review |
title_sort | treatment emergent dolutegravir resistance mutations in individuals naïve to hiv-1 integrase inhibitors: a rapid scoping review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536831/ https://www.ncbi.nlm.nih.gov/pubmed/37766338 http://dx.doi.org/10.3390/v15091932 |
work_keys_str_mv | AT taokaiming treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT rheesooyon treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT chucarolyn treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT avalosava treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT ahluwaliaamritk treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT guptaravindrak treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT jordanmichaelr treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview AT shaferrobertw treatmentemergentdolutegravirresistancemutationsinindividualsnaivetohiv1integraseinhibitorsarapidscopingreview |